Therapeutic approaches and targets for treatment of autoimmune bullous diseases.

Szczegóły
Abstrakt

Tytuł:: Therapeutic approaches and targets for treatment of autoimmune bullous diseases.
Autorzy:: Bardazzi F; Department of Specialized, Clinical and Experimental medicine, Division of Dermatology, University of Bologna, Italy.
Loi C; Department of Specialized, Clinical and Experimental medicine, Division of Dermatology, University of Bologna, Italy.
Chessa Marco A; Department of Specialized, Clinical and Experimental medicine, Division of Dermatology, University of Bologna, Italy.
Di Altobrando A; Department of Specialized, Clinical and Experimental medicine, Division of Dermatology, University of Bologna, Italy.
Filippi F; Department of Specialized, Clinical and Experimental medicine, Division of Dermatology, University of Bologna, Italy.
Lacava R; Department of Specialized, Clinical and Experimental medicine, Division of Dermatology, University of Bologna, Italy.
Viviani F; Department of Specialized, Clinical and Experimental medicine, Division of Dermatology, University of Bologna, Italy.
Balestri R; Division of Dermatology, Rare Disease Outpatient Service, Santa Chiara Hospital, Trento, Italy.
Leuzzi M; Department of Specialized, Clinical and Experimental medicine, Division of Dermatology, University of Bologna, Italy.
Sacchelli L; Department of Specialized, Clinical and Experimental medicine, Division of Dermatology, University of Bologna, Italy.
Źródło:: Dermatologic therapy [Dermatol Ther] 2021 Sep; Vol. 34 (5), pp. e15032. Date of Electronic Publication: 2021 Jul 14.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Publication: July/Aug. 2008- : Hoboken, NJ : Wiley-Blackwell
Original Publication: Copenhagen : Munksgaard, c1996-
MeSH Terms:: Autoimmune Diseases*/diagnosis
Autoimmune Diseases*/drug therapy
Epidermolysis Bullosa Acquisita*/diagnosis
Epidermolysis Bullosa Acquisita*/drug therapy
Pemphigoid, Bullous*
Pemphigus*/diagnosis
Pemphigus*/drug therapy
Skin Diseases, Vesiculobullous*/diagnosis
Skin Diseases, Vesiculobullous*/drug therapy
Humans
References:: Vassileva S, Drenovska K, Manuelyan K. Autoimmune blistering dermatoses as systemic diseases. Clin Dermatol. 2014;32(3):364-375.
Schmidt E, Goebeler M, Hertl M, et al. S2k guideline for the diagnosis of pemphigus vulgaris/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges. 2015;13:713-727.
Joly P, Horwath B, Patsatsi A, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34:1900-1913. https://doi.org/10.1111/jdv.16752.
Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346:321-327.
Martin LK, Werth V, Villanueva E, Segall J, Murrell DF. Interventions for pemphigus vulgaris and pemphigusd foliaceus. Cochrane Database Syst Rev. 2009;1:CD006263.
Didona D, Maglie R, Eming R, Hertl M. Pemphigus: current and future therapeutic strategies. Front Immunol. 2019;10:1418.
Porro AM, Hans Filho G, Santi CG. Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology. An Bras Dermatol. 2019;94(2 Suppl 1):20-32.
Santi CG, Gripp AC, Roselino AM, et al. Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology. An Bras Dermatol. 2019;94(2 Suppl 1):33-47.
Kridin K. Emerging treatment options for the management of pemphigus vulgaris. Ther Clin Risk Manag. 2018;14:757-778.
Cozzani E, Marzano AV, Caproni M. Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines. G Ital Dermatol Venereol. 2018;153:305-315.
Chams-Davatchi C, Mortazavizadeh A, Daneshpazhooh M, et al. Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2013 Oct;27(10):1285-1292.
Vorobyev A, Ludwig RJ, Schmidt E. Clinical features and diagnosis of epidermolysis bullosa acquisita. Expert Rev Clin Immunol. 2017;13:157-169.
Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res. 2014;306:103-124.
Caproni M, Antiga E, Melani L, Fabbri P. Italian Group for Cutaneous Immunopathology. Guidelines for the diagnosis and treatment of dermatitis herpetiformis. J Eur Acad Dermatol Venereol. 2009;23:633-638.
Vale ECSD, Dimatos OC, Porro AM, Santi CG. Consensus on the treatment of autoimmune bullous dermatoses: dermatitis herpetiformis and linear IgA bullous dermatosis - Brazilian Society of Dermatology. An Bras Dermatol. 2019;94(2 Suppl 1):48-55.
Gürcan HM, Ahmed AR. Current concepts in the treatment of epidermolysis bullosa acquisita. Expert Opin Pharmacother. 2011;12:1259-1268.
Żychowska M. Dapsone: a forgotten and underestimated treatment option for bullous pemphigoid? Br J Dermatol. 2017;177:1156-1157.
Sticherling M, Franke A, Aberer E, et al. An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol. 2017 Nov;177(5):1299-1305.
McCarty M, Fivenson D. Two decades of using the combination of tetracycline derivatives and niacinamide as steroid-sparing agents in the management of pemphigus: defining a niche for these low toxicity agents. J Am Acad Dermatol. 2014;71:475-479.
Chalmers JR, Wojnarowska F, Kirtschig G, et al. A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the bullous pemphigoid steroids and Tetracyclines (BLISTER) trial. Health Technol Assess. 2017;21:1-90.
Alzolibani AA, Zedan K. Macrolides in chronic inflammatory skin disorders. Mediators Inflamm. 2012;2012:159354.
Cooper SM, Powell J, Wojnarowska F. Linear IgA disease: successful treatment with erythromycin. Clin Exp Dermatol. 2002;27:677-679.
Wang Y, Yang B, Zhou G, Zhang F. Two cases of dermatitis Herpetiformis successfully treated with tetracycline and Niacinamide. Acta Dermatovenerol Croat. 2018;26:273-275.
De Simone C, Caldarola G, Perino F, Venier A, Guerriero G. Enteric-coated mycophenolate sodium as a steroid-sparing agent in pemphigus treatment: a retrospective study. Dermatol Ther. 2012;25:219-222.
Meurer M. Immunosuppressive therapy for autoimmune bullous diseases. Clin Dermatol. 2012;300:78-83.
Feliciani C, Cozzani E, Marzano AV, et al. Italian guidelines in pemphigus - adapted from the European dermatology forum (EDF) and European academy of dermatology and venerology (EADV). G Ital Dermatol Venereol. 2018;153:599-608.
Cozzani E, Cioni M, Gariazzo L, Burlando M, Parodi A. The management of autoimmune diseases in preconception, pregnancy and lactation. G Ital Dermatol Venereol. 2019;154:299-304.
Sukanjanapong S, Thongtan D, Kanokrungsee S, Suchonwanit P, Chanprapaph K. A comparison of azathioprine and mycophenolate Mofetil as adjuvant drugs in patients with pemphigus: a retrospective cohort study. Dermatol Ther. 2020 Feb;10(1):179-189.
Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol. 2007;143:1536-1542.
Sami N. Mycophenolate mofetil (MMF) in the treatment of epidermolysis bullosa acquisita (EBA) long-term follow-up. JAAD Case Rep. 2015 Aug 25;1(5):321-323. https://doi.org/10.1016/j.jdcr.2015.07.007.
Balestri R, Odorici G, Patrizi A, Infusino SD, Magnano M, Bardazzi F. Survey of bullous pemphigoid in an Italian university hospital: clinical-epidemiological characteristics and follow-up. G Ital Dermatol Venereol. 2018;15:613-618.
Gürcan HM, Ahmed AR. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol. 2009 Oct;161(4):723-731. https://doi.org/10.1111/j.1365-2133.2009.09246.x.
Tran KD, Wolverton JE, Soter NA. Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients. Br J Dermatol. 2013 Oct;169(4):916-921. https://doi.org/10.1111/bjd.12474.
Delaumenie S, Assikar S, Prudhomme R, et al. Methotrexate is safe and efficient as long-term treatment for bullous pemphigoid. Eur J Dermatol. 2019;29(2):217-218. https://doi.org/10.1684/ejd.2019.3501.
Awad A, Stüve O. Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms. Ther Adv Neurol Disord. 2009;2:50-61.
Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 guideline for diagnosis and treatment-guided by the European dermatology forum (EDF) in cooperation with the European academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2015;29:405-414.
Harman KE, Brown D, Exton LS, et al. British association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol. 2017;177:1170-1201.
Rose E, Wever S, Zilliken D, Linse R, Haustein UF, Bröcker EB. Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study. J Dtsch Dermatol Ges. 2005;3:200-206.
Daoud YJ, Amin KG. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases. Int Immunopharmacol. 2006;6:600-606.
Keskin DB, Stern JN, Fridkis-Hareli M, Ahmed AR. Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy. Cytokine. 2008;41:315-321.
Marzano AV, Tedeschi A, Polloni I, Crosti C, Cugno M. Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease. Clin Exp Immunol. 2013;17:76-81.
Feldman RJ, Christen WG, Ahmed AR. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy. Br J Dermatol. 2012;166:511-517.
Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology. 2010;117:861-869.
Gregoriou S, Efthymiou O, Stefanaki C, Rigopoulos D. Management of pemphigus vulgaris: challenges and solutions. Clin Cosmet Investig Dermatol. 2015;8:521-527.
Zambruno G, Borradori L. Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion. J Invest Dermatol. 2008;128:2745-2747.
Joly P, D'Incan M, Musette P. Rituximab for pemphigus vulgaris. N Engl J Med. 2007;356(5):521 author reply 521-2.
Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts. J Am Acad Dermatol. 2020 Mar;82(3):575-585.
Tavakolpour S, Mahmoudi H, Balighi K, Abedini R, Daneshpazhooh M. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review. Int Immunopharmacol. 2018;54:131-138.
Daneshpazhooh M, Balighi K, Mahmoudi H, et al. Iranian guideline for rituximab therapy in pemphigus patients. Dermatol Ther. 2019;32:e13016.
Loi C, Magnano M, Ravaioli GM, Sacchelli L, Patrizi A, Bardazzi F. Rituximab therapy in pemphigus: a long-term follow-up. Dermatol Ther. 2019. Jan;32(1):e12763. doi: https://doi.org/10.1111/dth.12763.
Lunardon L, Tsai KJ, Propert KJ, et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012 Sep;148(9):1031-1036.
Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017 May 20;389(10083):2031-2040.
Feldman RJ. Paradoxical worsening of pemphigus vulgaris following rituximab therapy. Br J Dermatol. 2015;173:858-859. https://doi.org/10.1111/bjd.13823.
Mahmoudi H, Tavakolpour S, Balighi K, et al. Rituximab in practice: clinical evaluation of patients with pemphigus after rituximab administration. Dermatol Ther. 2021;34:e14633.
Baykal C, Kılıç S, Küçükoğlu RJ. Paraneoplastic pemphigus seen in four patients with haematological malignancies formerly treated with rituximab. Eur Acad Dermatol Venereol. 2018 Feb;32(2):e50.
Du FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Auto Immun Highlights. 2017;8:12.
Szabolcs P, Reese M, Yancey KB, Hall RP, Kurtzberg J. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant. 2002;30:327-329.
Caso F, Iaccarino L, Bettio S, et al. Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab. Immunol Res. 2013;56:390-397.
Smith PF, Krishnarajah J, Nunn PA, et al. A phase I trial of PRN1008, a novel reversible covalent inhibitor of bruton's tyrosine kinase, in healthy volunteers. Br J Clin Pharmacol. 2017 Nov;83(11):2367-2376.
Izumi K, Bieber K, Ludwig RJ. Current clinical trials in pemphigus and pemphigoid. Front Immunol. 2019;10:978.
Kridin K, Ahn C, Huang WC, Ansari A, Sami N. Treatment update of autoimmune blistering diseases. Dermatol Clin. 2019;37:215-228.
Vico-Alonso C, Calleja-Algarra A, Aragón-Miguel R, Sánchez-Velázquez, Velasco-Tamariz V, Ortiz-Romero PL, Monsálvez-Honrubia V. Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: a case report. Dermatol Ther. 2019;32(2):e12829.
Maglie R, Hertl M. Pharmacological advances in pemphigoid. Curr Opin Pharmacol. 2019;46:34-43.
Majima Y, Yagi H, Tateishi C, et al. A successful treatment with ustekinumab in a case of antilaminin-γ1 pemphigoid associated with psoriasis. Br J Dermatol. 2013;168:1367-1369.
Le Guern A, Alkeraye S, Vermersch-Langlin A, Coupe P, Vonarx M. Bullous pemphigoid during ustekinumab therapy. JAAD Case Rep. 2015;1:359-360.
Contributed Indexing:: Keywords: autoimmune bullous disease; immunomodulating therapies; immunosuppressant therapies
Entry Date(s):: Date Created: 20210619 Date Completed: 20211101 Latest Revision: 20211101
Update Code:: 20240104
DOI:: 10.1111/dth.15032
PMID:: 34145701
: Czasopismo naukowe

Pełny tekst

Autoimmune bullous diseases are a heterogeneous group of diseases characterized by the development of cutaneous and mucosal vesicles, blisters, and finally erosions. The common pathogenetic mechanism is the presence of autoantibodies targeting structural proteins of the skin and mucous membranes (demosomes and hemidesmosomes): in the case of pemphigus, the antigens are intraepidermal, whereas in the case of pemphigoid, dermatitis herpetiformis, and epidermolysis bullosa acquisita they are subepidermal. Mucosal involvement typically affects the oral and ocular mucosa, but in some cases, the upper airways or the upper digestive tract are affected. The burden on patients' lives could be severe due to the impairment of normal feeding or breathing. In other cases, they may represent paraneoplastic syndromes. Since autoimmune bullous diseases may result in significant morbidity and mortality, depending on the grade of cutaneous and mucosal involvement, a prompt therapeutic approach is mandatory and, in recalcitrant cases, may be challenging. The first line therapy consists of corticosteroids, both topical and systemic. Once remission or control of the acute phase is obtained, adjuvant therapies need to be introduced in order to spare the corticosteroid load and minimize side effects such as iatrogenic diabetes or osteoporosis. Herein, we describe all current therapeutic approaches to autoimmune bullous diseases, also including emerging therapies.
(© 2021 Wiley Periodicals LLC.)

Informacja